MBRX
Moleculin Biotech IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$12.86M
P/E Ratio
—
EPS
$-28.42
Beta
1.67
52W High
$28.61
52W Low
$1.79
50-Day MA
$3.00
200-Day MA
$8.68
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.00
About Moleculin Biotech Inc
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of cancer drug candidates for the treatment of highly resistant viruses and tumors in the United States. The company is headquartered in Houston, Texas.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-25.01M |
| Operating Margin | 0.00% |
| Return on Equity | -256.10% |
| Return on Assets | -80.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.69 |
| Price-to-Book | 0.82 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.52 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $5.34M |
| Float | $5.29M |
| % Insiders | 0.84% |
| % Institutions | 3.34% |
Analyst Ratings
Consensus ($21.00 target)
1
Strong Buy2
BuyData last updated: 4/8/2026